Evercore ISI upgrades DexCom stock rating on growth outlook By Investing.com

Evercore ISI upgraded DexCom to Outperform with a $90 price target, forecasting ~25% EPS CAGR and >200bps of annual margin expansion through 2028 and double-digit top-line growth. DexCom reported Q4 2025 EPS $0.68 vs $0.65 consensus and revenue $1.26B vs $1.24B (13% YoY); Canaccord trimmed its PT to $95 (Buy) and Stifel reiterated Buy at $85. The company also added Google SVP Rick Osterloh to its board, reinforcing governance/strategic depth.

Analysis

Dexcom’s operational story is now a classic scale-vs-reimbursement bifurcation: small per-unit cost declines and higher ASP mix can create outsized cashflow if sell-through and payer coverage stay intact, but those same dynamics amplify downside if a coverage reversal or inventory destocking occurs. Expect the market’s multiple to be driven more by binary payer/coding wins and platform integrations over the next 6–18 months than by quarterly sell-through noise.

Second-order winners include sensor-component suppliers and any smartphone/wearable platform that secures tighter telemetry hooks (data stickiness creates annuity-like revenue optionality and raises switching costs for payers). Conversely, incumbent meter and strip suppliers, and non-integrated pump makers, face margin compression if CGM ubiquity forces deeper bundling or price competition. Integration with major OS/wearable ecosystems materially shortens the path to consumer adoption and indirect monetization (apps, alerts, SaaS for payers), shifting valuation from single-product multiples toward software-platform multiples over 12–36 months.

Key reversal risks: a negative payer/NIT decision or a manufacturing ramp that forces higher promotional/fulfillment costs can reverse the margin narrative quickly; litigation or a credible technical superiority claim from a rival would pressure ASPs and retention. Operationally, watch channel inventory and gross-margin cadence over the next two quarters as the earliest hard signal of sustainability versus a one-time margin pop. The consensus is focused on top-line growth; investors should be equally focused on coverage binaries and durable platform integrations as the determinant of multi-year returns.

Key Decisions for Investors

• Long-dated defined-risk bullish: Buy a 12–18 month DXCM call spread (long nearer-term ATM call, short higher-strike call) sized so max loss = 1–2% portfolio. Rationale: captures multi-quarter margin expansion and adoption with capped cost; exit/roll lower on a 15% price rally or if payer decision goes negative.
• Pair trade to isolate margin/share: Go long DXCM and short Abbott (ABT) or Medtronic (MDT) equal-dollar for 12 months. Rationale: isolates CGM share and pricing dynamics vs legacy meter suppliers; target 2:1 skew in notional toward DXCM if you want convexity to materializing platform wins. Trim at 25% relative outperformance or widen if payer signals improve.
• Tail-hedge around binary: Buy 6–9 month OTM puts on DXCM (small size, 0.5–1% portfolio) ahead of any near-term coverage rulings or major device approvals. Rationale: inexpensive protection vs a high-impact negative binary; take profit on >200% move in option premium or if ruling is positive.
• Event-driven tactical: If shares dip 8–12% on a transient quarter, add to long call-spread position and sell shorter-dated calls against it to fund carry (calendar flip). Rationale: leverages mean reversion while monetizing theta; cap upside to preserve IRR if margins disappoint.